Moderna Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Moderna Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10604
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:76
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Moderna Therapeutics Inc (Moderna Therapeutics) is a developer of messenger RNA therapeutics. The company provides in vivo drug modality that produces human proteins or antibodies inside patient cells. Its pipeline includes various drug modalities such as prophylactic vaccines, therapeutic vaccines, intratumoral immuno-oncology, localized therapeutics and liver intracellular. Moderna Therapeutics built a mRNA therapeutics platform, which is an in vivo drug technology which produces human proteins, antibodies and novel protein constructs inside patient cells, which are secreted or intracellularly active. The company offers therapeutics in the areas of infectious disease, rare liver disease, immuno-oncology and cardiovascular disease. Moderna Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Moderna Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Moderna Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Moderna Therapeutics Raises USD125 Million in Series H Preferred Equity Financing 12
Moderna Therapeutics Raises USD450 Million in Venture Financing 13
Moderna Therapeutics Raises Additional USD25 Million in Venture Financing 15
Onkaido Therapeutics To Raise US$20 Million In Venture Financing 16
Moderna Therapeutics Raises US$110 Million In Venture Financing 17
Moderna Therapeutics Raises US$40 Million In Series A Financing 18
Private Equity 19
Moderna Therapeutics Raises USD500 Million in Equity Financing 19
Partnerships 21
Moderna Therapeutics Enters into Agreement with Charles River Labs 21
AstraZeneca Enters into Co-Development Agreement with Moderna Therapeutics 22
Moderna Therapeutics Enters into Agreement with Pharmaceutical Product Development 23
Moderna Therapeutics Enters into Research Agreement with Institut Pasteur 24
Moderna Therapeutics Enters into Discovery Agreement with Karolinska Institutet and Karolinska University Hospital 25
Alexion Pharma And Moderna Therapeutics Enter Into Agreement To Develop Messenger RNA Therapeutics For Rare Diseases 26
AstraZeneca Expands Co-Development Agreement With Moderna Therapeutics For Messenger RNA Therapeutics 27
Licensing Agreements 28
AstraZeneca Enters into Licensing Agreement with Moderna Therapeutics 28
Vertex Pharma Enters into Licensing Agreement with Moderna Therapeutics 29
Merck Expands Licensing Agreement with Moderna Therapeutics 30
Moderna Therapeutics Enters into Licensing Agreement with Avacta Life Sciences 32
Moderna Therapeutics Amends Terms of Licensing Agreement with Merck 33
Equity Offering 35
Moderna Therapeutics Files Registration Statement for USD500 Million in IPO 35
Moderna Therapeutics Raises USD474 Million in Private Placement of Shares 36
AstraZeneca Invests USD140 Million in Moderna Therapeutics 37
Moderna Therapeutics Raises USD50 Million in Private Placement of Shares 38
Moderna Therapeutics Inc – Key Competitors 39
Moderna Therapeutics Inc – Key Employees 40
Moderna Therapeutics Inc – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 43
Corporate Communications 43
Sep 05, 2018: Dr. Wellington Sun joins Moderna as Head, vaccine strategy and regulatory affairs 43
Apr 04, 2018: Megan Pace Joins Moderna as Chief Corporate Affairs Officer 44
Jan 03, 2018: Dr. John Mendlein Joins Moderna as President, Corporate and Product Strategy 45
Oct 10, 2017: Stephen Berenson Joins Modernas Board of Directors 46
Aug 03, 2017: Industry Veteran Juan Andres Joins Moderna as Senior Vice President of Late Stage Technical Development and Manufacturing 47
Jul 27, 2017: Moncef M. Slaoui, Ph.D. Joins Moderna’s Board of Directors 49
Feb 22, 2017: Moderna Appoints Israel Ruiz to its Board of Directors 50
Product News 51
07/13/2017: Publication in Cell Demonstrates Modernas Zika mRNA Vaccine Prevents In Utero Transmission of Zika Virus in Mice, Protects Against Zika-Related Congenital Damage 51
Clinical Trials 53
Nov 15, 2017: Moderna Announces First-in-Human Dosing for Phase 1 Study (KEYNOTE-603) of mRNA-4157, a Personalized Cancer Vaccine, for the Treatment of Solid Tumors 53
Apr 27, 2017: Moderna Announces Positive Interim Phase 1 Clinical Data Demonstrating First mRNA Vaccine Candidate, mRNA-1440, Induces High Levels of Immunogenicity 54
Other Significant Developments 57
Jul 11, 2018: Moderna Provides Mid-Year Corporate Update 57
Jan 08, 2018: Moderna Announces an Array of Clinical Advances and Outlines 2018 Priorities; 19 Development Candidates, including 10 Clinical Programs, Highlight Productivity of mRNA Platform 61
Sep 14, 2017: Moderna Announces Pipeline and Corporate Update 64
Jul 27, 2017: Moderna Provides Update on mRNA Rare Disease R&D Strategy 70
Jan 09, 2017: Moderna Provides Pipeline and Full-Year Corporate Update 71
Appendix 76
Methodology 76
About GlobalData 76
Contact Us 76
Disclaimer 76

List of Tables
Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Moderna Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Moderna Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Moderna Therapeutics Raises USD125 Million in Series H Preferred Equity Financing 12
Moderna Therapeutics Raises USD450 Million in Venture Financing 13
Moderna Therapeutics Raises Additional USD25 Million in Venture Financing 15
Onkaido Therapeutics To Raise US$20 Million In Venture Financing 16
Moderna Therapeutics Raises US$110 Million In Venture Financing 17
Moderna Therapeutics Raises US$40 Million In Series A Financing 18
Moderna Therapeutics Raises USD500 Million in Equity Financing 19
Moderna Therapeutics Enters into Agreement with Charles River Labs 21
AstraZeneca Enters into Co-Development Agreement with Moderna Therapeutics 22
Moderna Therapeutics Enters into Agreement with Pharmaceutical Product Development 23
Moderna Therapeutics Enters into Research Agreement with Institut Pasteur 24
Moderna Therapeutics Enters into Discovery Agreement with Karolinska Institutet and Karolinska University Hospital 25
Alexion Pharma And Moderna Therapeutics Enter Into Agreement To Develop Messenger RNA Therapeutics For Rare Diseases 26
AstraZeneca Expands Co-Development Agreement With Moderna Therapeutics For Messenger RNA Therapeutics 27
AstraZeneca Enters into Licensing Agreement with Moderna Therapeutics 28
Vertex Pharma Enters into Licensing Agreement with Moderna Therapeutics 29
Merck Expands Licensing Agreement with Moderna Therapeutics 30
Moderna Therapeutics Enters into Licensing Agreement with Avacta Life Sciences 32
Moderna Therapeutics Amends Terms of Licensing Agreement with Merck 33
Moderna Therapeutics Files Registration Statement for USD500 Million in IPO 35
Moderna Therapeutics Raises USD474 Million in Private Placement of Shares 36
AstraZeneca Invests USD140 Million in Moderna Therapeutics 37
Moderna Therapeutics Raises USD50 Million in Private Placement of Shares 38
Moderna Therapeutics Inc, Key Competitors 39
Moderna Therapeutics Inc, Key Employees 40
Moderna Therapeutics Inc, Subsidiaries 42

List of Figures
Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Moderna Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Moderna Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • IRPC Public Company Limited:企業の戦略・SWOT・財務情報
    IRPC Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary IRPC Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Natera Inc (NTRA):企業の財務・戦略的SWOT分析
    Summary Natera Inc (Natera), formerly Gene Security Network Inc is a genetic testing and diagnostics company that develops and commercializes non-invasive methods for DNA analysis. The company offers Panorama, a non-invasive prenatal screening test that analyzes baby's DNA through a simple blood dra …
  • Evolving Systems Inc (EVOL):企業の財務・戦略的SWOT分析
    Summary Evolving Systems Inc (Evolving Systems) is a technology company that provides development, delivering and supporting technologies and vendor independent software solutions. The company offers software solutions such as real-time lifecycle marketing, dynamic sim allocation, tertio service act …
  • Ventas, Inc.:戦略・SWOT・企業財務分析
    Ventas, Inc. - Strategy, SWOT and Corporate Finance Report Summary Ventas, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Apogenix AG-製薬・医療分野:企業M&A・提携分析
    Summary Apogenix AG (Apogenix) is a biopharmaceutical company, developing immuno-oncology medicines for the treatment of cancer and other malignant diseases. Its pipeline drug candidates under clinical development include Asunercept (APG101), a CD95 ligand inhibitor, for the treatment of glioblastom …
  • Rexnord Corp (RXN):企業の財務・戦略的SWOT分析
    Rexnord Corp (RXN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Tiziana Life Sciences Plc (TILS):企業の財務・戦略的SWOT分析
    Tiziana Life Sciences Plc (TILS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Valeritas Inc:医療機器:M&Aディール及び事業提携情報
    Summary Valeritas Inc (Valeritas) is a medical technology company that develops and commercializes treatment solutions for diabetes. The company’s product includes V-Go insulin delivery device a wearable basal-bolus insulin delivery solution for patients with Type 2 diabetes. It also provides V-Go l …
  • Carbon Energy Corp (CRBO):石油・ガス:M&Aディール及び事業提携情報
    Summary Carbon Energy Corp (Carbon Energy), formerly Carbon Natural Gas Company is an independent oil and gas company. The company operates in the exploration, operation, management, and development of oil and gas properties in the Appalachian and Illinois Basin regions of the US. It holds interests …
  • Uniper SE (UN01):企業の財務・戦略的SWOT分析
    Uniper SE (UN01) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Simon Property Group Inc (SPG):企業の財務・戦略的SWOT分析
    Simon Property Group Inc (SPG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • The Indian Hotels Company Limited:企業の戦略・SWOT・財務情報
    The Indian Hotels Company Limited - Strategy, SWOT and Corporate Finance Report Summary The Indian Hotels Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Sangui BioTech International Inc (SGBI):企業の財務・戦略的SWOT分析
    Sangui BioTech International Inc (SGBI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Saudi Telecom Company:企業の戦略・SWOT・財務分析
    Saudi Telecom Company - Strategy, SWOT and Corporate Finance Report Summary Saudi Telecom Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • PetroChina Co Ltd Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    PetroChina Co Ltd Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary PetroChina Co Ltd Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on …
  • Dalet S.A. (DLT):企業の財務・戦略的SWOT分析
    Dalet S.A. (DLT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Lion Corporation:企業の戦略・SWOT・財務情報
    Lion Corporation - Strategy, SWOT and Corporate Finance Report Summary Lion Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Hoteli-Metropol AD Ohrid:企業の戦略・SWOT・財務情報
    Hoteli-Metropol AD Ohrid - Strategy, SWOT and Corporate Finance Report Summary Hoteli-Metropol AD Ohrid - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Banco Hipotecario SA (BHIP3):企業の財務・戦略的SWOT分析
    Banco Hipotecario SA (BHIP3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Slavneft-Megionneftegaz (MFGS):企業の財務・戦略的SWOT分析
    Summary Slavneft-Megionneftegaz (Megionneftegaz), a subsidiary of Slavneft, is an oil and gas company that operates oil fields. The company’s activities include appraisal of oil and gas fields, oil and gas production, and well drilling and operation. Megionneftegaz develops and introduces advanced t …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆